[
  {
    "ts": "2026-01-28T12:48:58+00:00",
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "62d39b3a-c971-3378-8437-69454e7eb072",
      "content": {
        "id": "62d39b3a-c971-3378-8437-69454e7eb072",
        "contentType": "STORY",
        "title": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
        "description": "",
        "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
        "pubDate": "2026-01-28T12:48:58Z",
        "displayTime": "2026-01-28T12:48:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C1nJneUQiExdSmoCae_JSg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63PlXOZomCP8u1XunFvtlg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cms-selects-next-batch-15-124858672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "TAK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T12:04:00+00:00",
    "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
    "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
    "url": "https://finance.yahoo.com/news/global-glioma-market-growth-driven-120400903.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "84028e1e-fe0c-3746-b3be-cdc043f031e1",
      "content": {
        "id": "84028e1e-fe0c-3746-b3be-cdc043f031e1",
        "contentType": "STORY",
        "title": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
        "description": "",
        "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
        "pubDate": "2026-01-28T12:04:00Z",
        "displayTime": "2026-01-28T12:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/global-glioma-market-growth-driven-120400903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/global-glioma-market-growth-driven-120400903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]